Jung Choi - 01 Feb 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role
Title: Chief Business and Strategy Officer
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Feb 2022
Net transactions value
-$97,962
Form type
4
Filing time
03 Feb 2022, 16:43:21 UTC
Previous filing
03 Sep 2021
Next filing
03 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +9,020 +4.9% 192,907 01 Feb 2022 Direct F1
transaction GBT Common Stock Tax liability $97,962 -3,340 -1.7% $29.33 189,567 01 Feb 2022 Direct F2
holding GBT Common Stock 25,000 01 Feb 2022 By Trust 1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -2,875 -100% $0.000000* 0 01 Feb 2022 Common Stock 2,875 Direct F1, F3
transaction GBT Restricted Stock Units Options Exercise $0 -3,125 -33% $0.000000 6,250 01 Feb 2022 Common Stock 3,125 Direct F1, F4
transaction GBT Restricted Stock Units Options Exercise $0 -3,020 -20% $0.000000 12,080 01 Feb 2022 Common Stock 3,020 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 9,020 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F4 The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F5 The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

Title: Chief Business and Strategy Officer